13 February 2024 in PLOS Global Public Health
Facemasks have been employed to mitigate the spread of SARS-CoV-2. The community effect of providing cloth facemasks on COVID-19 morbidity and mortality is unknown. In a cluster randomised trial in urban Bissau, Guinea-Bissau, clusters (geographical areas with an average of 19 houses), were randomised to an intervention or control arm using computer-generated random numbers. Between 20 July 2020 and 22 January 2021, trial participants (aged 10+ years) living in intervention clusters (n = 90) received two 2-layer cloth facemasks, while facemasks were only distributed later in control clusters (n = 91). All participants received information on COVID-19 prevention. Trial participants were followed through a telephone interview for COVID-19-like illness (3+ symptoms), care seeking, and mortality for 4 months. End-of-study home visits ensured full mortality information and distribution of facemasks to the control group. Individual level information on outcomes by trial arm was compared in logistic regression models with generalised estimating equation-based correction for cluster. Facemasks use was mandated. Facemask use in public areas was assessed by direct observation. We enrolled 39,574 trial participants among whom 95% reported exposure to groups of >20 persons and 99% reported facemasks use, with no difference between trial arms. Observed use was substantially lower (~40%) with a 3%, 95%CI: 0–6% absolute difference between control and intervention clusters. Half of those wearing a facemask wore it correctly. Few participants (532, 1.6%) reported COVID-19-like illness; proportions did not differ by trial arm: Odds Ratio (OR) = 0.81, 95%CI: 0.57–1.15. 177 (0.6%) participants reported consultations and COVID-19-like illness (OR = 0.83, 95%CI: 0.56–1.24); 89 participants (0.2%) died (OR = 1.34, 95%CI: 0.89–2.02). Hence, though trial participants were exposed to many people, facemasks were mostly not worn or not worn correctly. Providing facemasks and messages about correct use did not substantially increase their use and had limited impact on morbidity and mortality. Trial registration: clinicaltrials.gov: NCT04471766.
13 May 2023 in International Journal of Infectious Diseases
JMJustiniano S.D. Martins
Campaigns with measles vaccine (C-MV) are conducted to eradicate measles, but prior studies indicate that MV reduces non-measles mortality and hospital admissions too. We hypothesized that C-MV reduces death/hospital admission by 30%. Between 2016-2019, we conducted a non-blinded cluster-randomized trial randomizing village clusters in rural Guinea-Bissau to a C-MV targeting children aged 9-59 months. In Cox proportional hazards models, we assessed the effect of C-MV, obtaining hazard ratios (HR) for the composite outcome (death/hospital admission). We also examined potential effect modifiers. Among 18,411 children (9636 in 111 intervention clusters/8775 in 110 control clusters), 379 events occurred (208 intervention/171 control) during a median follow-up period of 22 months. C-MV did not reduce the composite outcome (HR 1.12, 95% confidence interval 0.88-1.41). Mortality among enrolled children (5.3 intervention and 4.6 control, per 1000 person-years) was approximately half the pre-trial mortality rate (11.1 intervention and 8.9 control, per 1000 person-years). Neither planned nor explorative analyses of potential effect modifiers explained the contrasting results to prior studies. C-MV did not reduce overall mortality or hospital admission. This might be explained by changes in disease patterns, baseline differences in health status, and/or modifying effects of other campaigns during follow-up.
1 January 2022 in SSRN Electronic Journal
Background: Oral Polio Vaccine (OPV) may strengthen the immune system broadly improving resistance to non-polio-infections. Prior to COVID-19 vaccines being widely available, we tested if OPV could reduce the risk of illness and mortality. Methods: We conducted an unblinded cluster-randomised trial. Houses in urban Guinea-Bissau were randomised 1:1 to intervention or control. Residents aged 50+ years were invited to participate. Participants received bivalent OPV (single dose) or nothing and were followed for 6 months. Rates of mortality, admissions, and consultation for infections (primary composite outcome) were compared in Cox proportional hazards models adjusted for age and area of residence. Secondary outcomes included mortality, admissions, consultations, and symptoms of infection. Findings: Among 3729 enrolled participants, we followed 3726 (OPV: 1580; Control: 2146) and registered 66 deaths, 97 admissions and 298 consultations for infections. OPV did not reduce the risk of the composite outcome, hazard ratio (HR)=0.97 (95%CI: 0.79-1.18). The effect differed by sex (HR=0.71 (0.51-0.98) for men; HR=1.18 (0.91-1.52) for women; p for same effect=0.02) and by BCG scar-status (HR=0.70 (0.49-0.99) in scar-positive; HR=1.13 (0.89-1.45) in scar-negative participants; p=0.03). OPV had no overall significant effect on mortality (HR=0.96 (0.59-1.55)), admissions (HR=0.76 (0.49-1.17)) or recorded consultations (HR=0.99 (0.79-1.25)). Only 2/590 participants with reported COVID-19 test stated positive results. OPV was associated with increased reporting of symptoms of infection (6050 episodes; HR=1.10 (1.03-1.17)). Interpretation: OPV increased reported symptoms of infections but did not increase the risk of severe infections. OPV appeared to benefit men and BCG-scar positive participants. Trial Registration: Registration: www.clinicaltrials.gov/NCT04445428 Funding: University of Southern Denmark supported the trial. ABF was supported by an Ascending investigator grant from Lundbeck Foundation (R313-2019-635) and a Sapere Aude grant from Independent Research Fund Denmark (9060-00018B). Declaration of Interest: The authors have no conflicts of interest. Ethical Approval: The trial was approved by the Comité Nacional de Ética na Saúde, Guinea-Bissau on 21 May 2020 (Ref: 077/CNES/INASA/2020) and received consultative approval from The National Committee on Health Research Ethics, Denmark on 16 June 2020 (Ref: 2008258).